Issue 48, 2021

ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV

Abstract

We report a distinct difference in the interactions of the glycans of the host-cell receptor, ACE2, with SARS-CoV-2 and SARS-CoV S–protein receptor-binding domains (RBDs). Our analysis demonstrates that the ACE2 glycan at N322 enhances interactions with the SARS-CoV-2 RBD while the ACE2 glycan at N90 may offer protection against infections of both coronaviruses depending on its composition. The interactions of the ACE2 glycan at N322 with SARS-CoV RBD are blocked by the presence of the RBD glycan at N357 of the SARS-CoV RBD. The absence of this glycosylation site on SARS-CoV-2 RBD may enhance its binding with ACE2.

Graphical abstract: ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV

Supplementary files

Article information

Article type
Communication
Submitted
30 Apr 2021
Accepted
18 May 2021
First published
18 May 2021

Chem. Commun., 2021,57, 5949-5952

ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV

A. Acharya, D. L. Lynch, A. Pavlova, Y. T. Pang and J. C. Gumbart, Chem. Commun., 2021, 57, 5949 DOI: 10.1039/D1CC02305E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements